Recurrent Pregnancy Loss and Endometrial Metabolism: Early Evidence

Unexplained recurrent pregnancy loss was associated with an endometrial lipid-metabolism signature in a prospective study of 80 women. Researchers compared endometrial tissue and plasma from women with pregnancy loss, implantation failure and fertile controls. The findings do not establish a cause of miscarriage, a validated diagnostic test or a benefit from supplements.

Comprehensive endometrial and plasma profiling in 19 women with recurrent pregnancy loss (RPL), 41 with recurrent implantation failure (RIF), and 20 fertile controls
Depleted medium-chain acylcarnitines alongside elevated storage lipids (diglycerides and triglycerides) detected during the window of implantation
No distinct metabolic signature was identified in RIF in this cohort; the absence of a detected signature does not establish a different cause for every patient.
The study explores endometrial metabolism as a possible research direction in unexplained recurrent pregnancy loss.

A pregnancy is confirmed, only to halt weeks later. Even after an appropriate evaluation, many couples are left without a definitive explanation. Testing is selected according to clinical history; ASRM does not recommend routine inherited thrombophilia panels for recurrent pregnancy loss. What is occurring at the cellular level inside the uterine lining of women facing “unexplained recurrent pregnancy loss” at the exact moment of implantation?

A study offers a compelling biological clue: direct profiling of the endometrium during the peri-implantation window revealed that metabolite concentrations associated with fatty acid metabolism and lipid storage differed in women with recurrent pregnancy loss compared to fertile controls.

The findings, published in the journal Reproductive BioMedicine Online (RBMO), were conducted by a research team from the University of Angers and Angers University Hospital in France. The investigators compared the metabolomic profiles of plasma and endometrial tissue across 80 women undergoing assisted reproductive technology (ART): 19 women with unexplained recurrent pregnancy loss (uRPL), 41 with recurrent implantation failure (RIF), and 20 fertile controls undergoing treatment for male-factor subfertility.

Study design: plasma and endometrial sampling around implantation

What distinguishes this study from routine clinical workups is that rather than relying solely on peripheral blood, the researchers directly analyzed endometrial tissue harvested during the exact period when an embryo would attach.

Endometrial biopsies and blood draws were performed 5 to 9 days after ovulation (biopsies were scheduled 6 to 10 days after a positive ovulation test)—the physiologically defined window of implantation (WOI). Using high-performance liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS), the investigators profiled up to 630 distinct metabolites spanning amino acids, acylcarnitines, phospholipids, sphingolipids, ceramides, and glycerides.

Among these, 494 metabolites in plasma and 228 in endometrial tissue were reliably quantified. Employing multivariate statistics and machine learning algorithms, the team assessed whether metabolic signatures could reliably segregate the three clinical cohorts.

The results revealed a striking contrast:

Recurrent Implantation Failure (RIF): Neither plasma nor endometrial samples exhibited a distinct, reproducible metabolomic fingerprint separating them from controls.
Unexplained Recurrent Pregnancy Loss (uRPL): Endometrial tissue exhibited a distinct, pronounced metabolomic signature compared to fertile controls.

No distinct plasma signature was identified for uRPL in this study. This does not prove that systemic metabolism is normal or that all relevant changes are confined to the endometrium.

Sixteen metabolites linked to altered fatty-acid metabolism

Through orthogonal partial least squares discriminant analysis (OPLS-DA) and variable importance in projection (VIP) scoring, the researchers identified a signature of 16 key endometrial metabolites that distinguished women with uRPL.

The most prominent feature was a significant reduction in acylcarnitines, particularly medium-chain acylcarnitines.

Conversely, neutral storage lipids—including specific diglycerides (DGs) and triglycerides (TGs)—as well as select ceramides and phospholipids, were significantly elevated. Together, this metabolic pattern indicates a profound disturbance in how the endometrium processes fatty acids:

Acylcarnitines participate in fatty-acid metabolism, including the mitochondrial transport of long-chain fatty acids for β-oxidation and cellular ATP production.
When acylcarnitines are depleted while storage glycerides accumulate, it suggests an impaired capacity to mobilize and burn fatty acids for energy, shifting lipid balance toward intracellular storage instead.

Lipids do not simply serve as inert stored energy. They constitute structural building blocks for cell membranes, drive secondary intracellular signaling cascades, and fuel the rapid cellular reorganization required to prepare the endometrium for gestation. In women with uRPL, the physiological equilibrium between lipid transport, fatty acid consumption, and lipid storage appears fundamentally altered.

Decidualization: a proposed mechanism, not proven causation

The research team highlighted decidualization as the primary physiological process likely compromised by this metabolic shift.

Following ovulation, rising progesterone levels trigger endometrial stromal cells to differentiate into specialized, secretory decidual cells. Decidualization is not merely endometrial thickening; it is a bioenergetically demanding transformation where stromal cells reprogram their metabolism to nourish the incoming blastocyst, orchestrate local immune tolerance, and strictly control trophoblast invasion.

The authors hypothesized that impaired medium-chain fatty acid utilization disrupts the intense energy production required for optimal decidualization. An endometrium incapable of meeting these cellular bioenergetic demands may allow initial implantation, but fail to provide the sustained metabolic and structural support required to maintain the developing embryo, ultimately culminating in early pregnancy loss.

However, this does not mean that “a simple dietary deficiency in fatty acids causes miscarriage.”

This was an observational metabolomic study identifying a localized biochemical association. It was not an intervention trial testing whether modifying lipid intake or taking omega-3 supplements prevents pregnancy loss. These findings should not be interpreted as a justification for self-prescribing fatty acid supplements to treat recurrent miscarriage.

What the RIF comparison can and cannot establish

Another critical insight is the divergence between RIF and RPL.

In clinical practice, these two diagnoses are often grouped together as unexplained reproductive failures. One describes an embryo’s inability to implant in the uterine wall, while the other involves repeated embryonic arrest and demise after implantation has commenced.

In this study, RIF patients showed no distinct endometrial metabolomic clustering, whereas uRPL patients exhibited clear, localized lipid dysregulation.

The different findings warrant further study; they do not establish wholly separate mechanisms for RIF and RPL. The authors note that RIF-group heterogeneity, lack of embryo genetic assessment and predominantly early-stage transfers may have limited detection of a signature.

Why endometrial metabolomics still needs clinical validation

For patients navigating recurrent miscarriage, few experiences are more disorienting than undergoing batteries of exhaustive diagnostic workups only to be told: “Everything looks completely normal.”

Established RPL assessments and research metabolomics answer different questions. Uterine imaging and indicated blood or genetic tests remain clinically useful; this study does not show that experimental endometrial metabolomics should replace them.

The study identified 16 highly relevant metabolites within an exploratory endometrial classification analysis. This is a candidate biomarker finding, not validation of a 16-metabolite diagnostic panel for routine care.

Nonetheless, significant clinical hurdles remain before endometrial metabolomic testing can be implemented in routine fertility clinics. The RPL cohort in this pilot investigation was small (19 patients), and extensive external validation across larger, multi-center prospective cohorts is required to establish clinical reference ranges.

Even so, the study expands our perspective on recurrent pregnancy loss. When early pregnancies repeatedly arrest, the etiology may not reside exclusively within embryonic genetics, but within the bioenergetic programming of the maternal endometrium—specifically, how uterine cells process and burn fats during the crucial days of implantation.